Literature DB >> 26155397

CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression.

Nathalie Bonnefoy1, Jérémy Bastid2, Gilles Alberici2, Armand Bensussan3, Jean-François Eliaou4.   

Abstract

We report that CD39-expressing-melanoma cells inhibited both T-cell proliferation and the generation of cytotoxic effectors in an adenosine-dependent manner, and that treatment with a CD39-blocking antibody alleviated tumor-mediated immunosuppression. Thus, blocking CD39 ectonucleotidase may represent a novel immunotherapeutic strategy to restore antitumor immunity.

Entities:  

Keywords:  CD39, immune checkpoints, A2A receptor, adenosine, PD1

Year:  2015        PMID： 26155397      PMCID： PMC4485743          DOI： 10.1080/2162402X.2014.1003015

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression.

Authors:  Fanny Chalmin; Grégoire Mignot; Mélanie Bruchard; Angélique Chevriaux; Frédérique Végran; Aziz Hichami; Sylvain Ladoire; Valentin Derangère; Julie Vincent; David Masson; Simon C Robson; Gerard Eberl; Jean René Pallandre; Christophe Borg; Bernhard Ryffel; Lionel Apetoh; Cédric Rébé; Francois Ghiringhelli
Journal:  Immunity       Date:  2012-03-08       Impact factor: 31.745

2.  Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.

Authors:  Sebastian F M Häusler; Itsaso Montalbán del Barrio; Jenny Strohschein; P Anoop Chandran; Jörg B Engel; Arnd Hönig; Monika Ossadnik; Evi Horn; Birgitt Fischer; Mathias Krockenberger; Stefan Heuer; Ahmed Adel Seida; Markus Junker; Hermann Kneitz; Doris Kloor; Karl-Norbert Klotz; Johannes Dietl; Jörg Wischhusen
Journal:  Cancer Immunol Immunother       Date:  2011-06-03       Impact factor: 6.968

3.  A2A adenosine receptor protects tumors from antitumor T cells.

Authors:  Akio Ohta; Elieser Gorelik; Simon J Prasad; Franca Ronchese; Dmitriy Lukashev; Michael K K Wong; Xiaojun Huang; Sheila Caldwell; Kebin Liu; Patrick Smith; Jiang-Fan Chen; Edwin K Jackson; Sergey Apasov; Scott Abrams; Michail Sitkovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-17       Impact factor: 11.205

4.  Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Authors:  Jeremy Bastid; Anne Regairaz; Nathalie Bonnefoy; Cécile Déjou; Jérôme Giustiniani; Caroline Laheurte; Stéphanie Cochaud; Emilie Laprevotte; Elisa Funck-Brentano; Patrice Hemon; Laurent Gros; Nicole Bec; Christian Larroque; Gilles Alberici; Armand Bensussan; Jean-François Eliaou
Journal:  Cancer Immunol Res       Date:  2014-11-17       Impact factor: 11.151

5.  Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.

Authors:  Mickaël Michaud; Isabelle Martins; Abdul Qader Sukkurwala; Sandy Adjemian; Yuting Ma; Patrizia Pellegatti; Shensi Shen; Oliver Kepp; Marie Scoazec; Grégoire Mignot; Santiago Rello-Varona; Maximilien Tailler; Laurie Menger; Erika Vacchelli; Lorenzo Galluzzi; François Ghiringhelli; Francesco di Virgilio; Laurence Zitvogel; Guido Kroemer
Journal:  Science       Date:  2011-12-16       Impact factor: 47.728

6.  Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice.

Authors:  Shaun W Jackson; Tomokazu Hoshi; Yan Wu; Xiaofeng Sun; Keiichi Enjyoji; Eva Cszimadia; Christian Sundberg; Simon C Robson
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

7.  Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.

Authors:  Yuting Ma; Sandy Adjemian; Stephen R Mattarollo; Takahiro Yamazaki; Laetitia Aymeric; Heng Yang; João Paulo Portela Catani; Dalil Hannani; Helene Duret; Kim Steegh; Isabelle Martins; Frederic Schlemmer; Mickaël Michaud; Oliver Kepp; Abdul Qader Sukkurwala; Laurie Menger; Erika Vacchelli; Nathalie Droin; Lorenzo Galluzzi; Roman Krzysiek; Siamon Gordon; Philip R Taylor; Peter Van Endert; Eric Solary; Mark J Smyth; Laurence Zitvogel; Guido Kroemer
Journal:  Immunity       Date:  2013-04-04       Impact factor: 31.745

8.  CD73-deficient mice are resistant to carcinogenesis.

Authors:  John Stagg; Paul A Beavis; Upulie Divisekera; Mira C P Liu; Andreas Möller; Phillip K Darcy; Mark J Smyth
Journal:  Cancer Res       Date:  2012-03-06       Impact factor: 12.701

9.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

10.  Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling.

Authors:  A Ko; A Kanehisa; I Martins; L Senovilla; C Chargari; D Dugue; G Mariño; O Kepp; M Michaud; J-L Perfettini; G Kroemer; E Deutsch
Journal:  Cell Death Differ       Date:  2013-09-13       Impact factor: 15.828
  10 in total
  21 in total

1.  Potential effect of tumor-specific Treg-targeted antibodies in the treatment of human cancers: A bioinformatics analysis.

Authors:  Luigi Cari; Giuseppe Nocentini; Graziella Migliorati; Carlo Riccardi
Journal:  Oncoimmunology       Date:  2017-11-09       Impact factor: 8.110

Review 2.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

3.  Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity.

Authors:  Xian-Yang Li; Achim K Moesta; Christos Xiao; Kyohei Nakamura; Mika Casey; Haiyan Zhang; Jason Madore; Ailin Lepletier; Amelia Roman Aguilera; Ashmitha Sundarrajan; Celia Jacoberger-Foissac; Clifford Wong; Tracy Dela Cruz; Megan Welch; Alana G Lerner; Bradley N Spatola; Vanessa B Soros; John Corbin; Ana C Anderson; Maike Effern; Michael Hölzel; Simon C Robson; Rebecca L Johnston; Nicola Waddell; Corey Smith; Tobias Bald; Nishamol Geetha; Courtney Beers; Michele W L Teng; Mark J Smyth
Journal:  Cancer Discov       Date:  2019-11-07       Impact factor: 39.397

Review 4.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 5.  FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Ther Targets       Date:  2018-04-10       Impact factor: 6.902

6.  IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population.

Authors:  Clément Barjon; Henri-Alexandre Michaud; Angeline Fages; Cécile Dejou; Alexandre Zampieri; Laetitia They; Aurélie Gennetier; Françoise Sanchez; Laurent Gros; Jean-François Eliaou; Nathalie Bonnefoy; Virginie Lafont
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

7.  Response of the ileum transcriptome to probiotic and fructo-oligosaccharides in Taiping chicken.

Authors:  Lintong Luo; Fang Ma; Qianning Wang
Journal:  J Appl Genet       Date:  2021-02-27       Impact factor: 3.240

Review 8.  Targeting adenosine in cancer immunotherapy: a review of recent progress.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Anticancer Ther       Date:  2017-04-27       Impact factor: 4.512

9.  The role of NK cells and CD39 in the immunological control of tumor metastases.

Authors:  Haiyan Zhang; Dipti Vijayan; Xian-Yang Li; Simon C Robson; Nishamol Geetha; Michele W L Teng; Mark J Smyth
Journal:  Oncoimmunology       Date:  2019-04-02       Impact factor: 8.110

Review 10.  Therapy-induced microenvironmental changes in cancer.

Authors:  Yuting Ma; Heng Yang; Jonathan M Pitt; Guido Kroemer; Laurence Zitvogel
Journal:  J Mol Med (Berl)       Date:  2016-03-02       Impact factor: 4.599
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.